Friday, 23 October 2026
MS-2 Step approved to 70 days, Record GP training place allocation, Super access report crackdown
- 01
TGA expands MS-2 Step indications to 70 days’ gestation
Following recent pharmacy access reforms, the TGA has now approved MS-2 Step for medical abortion up to 70 days’ gestation and for medical management of missed miscarriage up to the same gestation. The abortion indication extends the previous approved limit by seven days, while gestational age for missed miscarriage is determined by ultrasound. The TGA reported no new safety concerns, with side effects consistent with the known effects of mifepristone and misoprostol, and said evidence supported efficacy for both newly approved uses. The changes are now in effect, but Pharmaceutical Benefits Scheme subsidies have not yet been extended to the new uses.
via RACGP newsGP · also covered by The Medical Republic
- 02
Commonwealth allocates record 2100 GP training places for 2028
The Federal Government has allocated a record 2100 GP training places across Australia for 2028. The RACGP will receive an extra 87 Commonwealth-funded places, bringing its total to 1627, including 37 additional rural training positions. The allocation also includes places administered by the Australian College of Rural and Remote Medicine, with at least half of the investment dedicated to Rural Generalist and rural GP training. The expansion follows the RACGP filling every available training place for 2027 and reporting a 40% increase in training numbers over the past two years. Federal Health and Ageing Minister Mark Butler said the investment aims to grow the GP workforce in areas of greatest need.
via RACGP newsGP · also covered by The Medical Republic
- 03
ATO crackdown targets misleading medical reports for super access
Health practitioners face fines and possible loss of registration for providing false or misleading medical reports supporting compassionate release of superannuation, the ATO and AHPRA have warned. The ATO has begun more than 160 reviews and audits since 1 July 2025 and imposed over $1.5 million in penalties, including a fine of about $30,000 against one practitioner whose report contained inaccurate clinical information. AHPRA said suspected cases could be referred to tribunals for alleged professional misconduct; one practitioner has had their registration suspended in connection with a patient’s cosmetic surgery, while others face ongoing proceedings. Regulators are particularly targeting arrangements involving short online consultations, report templates and pressure on patients to fund medical or cosmetic procedures from retirement savings. Approved compassionate-release applications fell 5% from the previous year, although the total value of withdrawals rose 2% to more than $1.4 billion.
- 04
PBAC recommendation may ease impact of monthly goserelin withdrawal
A PBAC recommendation could secure another treatment option for thousands of women affected by the looming withdrawal of monthly goserelin. The potential replacement could also reduce the need for frequent injections. The source gives limited detail and does not identify the recommended treatment or timing.
- 05
Updated guidance expands penicillin allergy testing in general practice
Updated ASCIA guidelines now support GPs to assess reported penicillin allergies and identify low-risk adults and children for supervised oral challenges in general practice. Around 10% of Australians report a penicillin allergy, but fewer than 1% of the population are thought to be genuinely allergic. The guidance provides clearer risk criteria, while patients with intermediate- or high-risk histories, including recent anaphylaxis or severe delayed cutaneous reactions, continue to require specialist assessment. Online training and practical resources accompany the guidelines, and challenges require appropriate protocols and access to emergency treatment for allergic reactions. No dedicated Medicare Benefits Schedule item currently covers penicillin allergy challenges in general practice, although ASCIA has applied for new antibiotic challenge items.
- 06
UK approves once-weekly insulin efsitora alfa for type 2 diabetes
The UK Medicines and Healthcare Products Regulatory Agency approved once-weekly efsitora alfa for adults with type 2 diabetes. The insulin injection, also known as Onswik, is made by Eli Lilly. The National Institute for Health and Care Excellence recommended the treatment in August, citing trial evidence that it was as effective as long-acting insulins already widely used for type 2 diabetes. Unlike current options, Onswik requires injection only once a week.
via BMJ
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.